Composite 30-day end point (death, myocardial infarction or urgent repeat revascularization) event rates for the 7 GPIIb-IIIa interventional trials.

This was not the prespecified primary end point of RESTORE or RAPPORT. RESTORE trial end points listed here are for the published post-hoc analysis including only urgent repeat revascularization. RESTORE trial end points listed here differ from those of the other trials in that only patients with successful crossing of the lesion with the guidewire were included in the efficacy analysis of RESTORE, whereas all randomized patients were included in the other studies. RAPPORT trial end points listed here are for secondary end point of death, myocardial infarction or urgent repeat target vessel revascularization. ^*EPISTENT trial groups compared with reference group of Placebo + Stent; thus, the “placebo control” for the Abciximab + PTCA group underwent stenting rather than PTCA.

Abbreviations: B, bolus; B + I, bolus plus infusion; CAPTURE, C7E3 AntiPlatelet Therapy in Unstable REfractory angina; EPIC, Evaluation of c7E3 for Prevention of Ischemic Complications; EPILOG, Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade; EPISTENT, Evaluation of Platelet Inhibition in STENTing; IMPACT, Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis; LDH, low-dose, weight-adjusted heparin; MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; RAPPORT, ReoPro And Primary PTCA Organization and Randomized Trial; RESTORE, Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis; SDH, standard-dose, weight-adjusted heparin; 135/.5 and 135/.75, eptifibatide doses: 135 μg/kg bolus, followed by infusions of 0.5 or 0.75 μg/kg/min.

Reproduced with permission from Lincoff et al. JACC 35: 1103, 2000.